Formoterol
- Generic Name
- Formoterol
- Brand Names
- Bevespi, Breyna, Breztri, Duaklir, Duaklir Genuair, Dulera, Foradil, Oxeze, Perforomist, Symbicort, Zenhale
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N2O4
- CAS Number
- 73573-87-2
- Unique Ingredient Identifier
- 5ZZ84GCW8B
- Background
Formoterol is an inhaled beta-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled ...
- Indication
Formoterol is indicated in various formulations for the treatment of asthma and COPD. For the treatment of COPD, formoterol is available as a single-entity inhalation solution, in combination with the long-acting muscarinic antagonists (LAMAs) aclidinium and glycopyrronium, and in combination with the corticosteroid budesonide. For the treatment of asthma, f...
- Associated Conditions
- Asthma, Bronchial Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Associated Therapies
- Maintenance therapy
Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control
- Conditions
- Interventions
- First Posted Date
- 2006-10-27
- Last Posted Date
- 2011-08-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1732
- Registration Number
- NCT00393458
- Locations
- 🇬🇧
Novartis Investigator Site, Swansea, United Kingdom
🇪🇸Novartis Investigative Site, Madrid, Spain
🇹🇷Novartis, Istanbul, Turkey
SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma
- Conditions
- First Posted Date
- 2006-02-08
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT00288379
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
SHARE - Symbicort and Health Economics in a Real Life Evaluation
- Conditions
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1970
- Registration Number
- NCT00259766
- Locations
- 🇸🇪
Reseearch Site, Perstorp, Sweden
🇸🇪Research Site, Örebro, Sweden
🇸🇪Research site, Ödeshög, Sweden
Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary Disease
- Conditions
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2011-10-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 847
- Registration Number
- NCT00134979
To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD
- Conditions
- Interventions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 799
- Registration Number
- NCT00064415
- Locations
- 🇺🇸
Advances in Medicine, Rancho Mirage, California, United States
🇺🇸Inland Clinical Research, Inc., Riverside, California, United States
🇺🇸New Horizon Health Research, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.